

Press Release

Strangvac®, a vaccine against equine strangles released for sales in Italy

Stockholm, December 13th, 2022 - Intervacc AB (publ) announces today that the first batch of Strangvac®, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the vaccine in Italy and in a number of other European countries.

"The first batch of Strangvac® for Italy has now been released. This means that sales of Strangvac® in Italy can begin", explains Andreas Johansson, Logistics Manager at Intervacc.

"Streptococcus equi causes significant suffering in populations of horses in Italy. I have studied the strains recovered from Italian horses as they cause disease to better understand how this pathogen spreads. Therefore, I am delighted that we now have an additional tool with which to help keep our horses safe," says Dr. Silvia Preziuso at the Università di Camerino.

"Strangvac® is approved for sale and marketing in the EU as well as the UK and Norway. Strangvac® has been launched in Sweden, Denmark, the UK, France, Germany, the Benelux region, Austria, Ireland, Poland and now also in Italy. Outbreaks of equine strangles occur regularly and the disease cause great suffering and economic cost in the region and across Europe. Italy is an important equine market, and this is significant milestone for our continued launch around Europe." comments Andreas Andersson, CEO of Intervacc.

For more information please contact:

Andreas Andersson, CEO

Phone: +46-8-120 10 601, cell +46-73-335 99 70 E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on December 13, 2022, 13.30 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

About equine strangles

Equine strangles, caused by *Streptococcus equi*, is the most frequently diagnosed infectious disease of horses, and affects horses all over the world with one exception Iceland where the import of horses is prohibited. *Streptococcus equi* invades the lymph nodes of head and neck, causing them to swell and form abscesses that can literally strangle, in around 2% of cases, the horse to death. Some of the horses that recover from strangles remain persistently infected. These apparently healthy animals shed bacteria into the environment and spread the disease to other horses with which they come into contact.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10